Fortunato Ciardiello, MD, PhD, University of Campania

Articles by Fortunato Ciardiello, MD, PhD, University of Campania

Future Directions in Later Line Therapy for mCRC

ByFortunato Ciardiello, MD, PhD, University of Campania,Axel Grothey, MD, West Cancer Center & Research Institute,Heinz-Josef Lenz, MD, FACP, USC Norris Comprehensive Cancer Center

June 29th 2020

Key Trials in mCRC: I/O Combination Therapies

ByFortunato Ciardiello, MD, PhD, University of Campania,Axel Grothey, MD, West Cancer Center & Research Institute,Heinz-Josef Lenz, MD, FACP, USC Norris Comprehensive Cancer Center

June 29th 2020

Role of I/O Combination Therapies in mCRC

ByFortunato Ciardiello, MD, PhD, University of Campania,Axel Grothey, MD, West Cancer Center & Research Institute,Heinz-Josef Lenz, MD, FACP, USC Norris Comprehensive Cancer Center

June 29th 2020

Using I/O in MSI-H Tumors in mCRC

ByFortunato Ciardiello, MD, PhD, University of Campania,Axel Grothey, MD, West Cancer Center & Research Institute,Heinz-Josef Lenz, MD, FACP, USC Norris Comprehensive Cancer Center

June 29th 2020

Sequencing in mCRC: Later-Line Therapies

ByFortunato Ciardiello, MD, PhD, University of Campania,Axel Grothey, MD, West Cancer Center & Research Institute,Heinz-Josef Lenz, MD, FACP, USC Norris Comprehensive Cancer Center

June 29th 2020

Therapeutic Agents in Relapsed/Refractory mCRC

ByFortunato Ciardiello, MD, PhD, University of Campania,Axel Grothey, MD, West Cancer Center & Research Institute,Heinz-Josef Lenz, MD, FACP, USC Norris Comprehensive Cancer Center

June 29th 2020

CORRECT, RECOURSE, and ReDOS Trials in mCRC

ByFortunato Ciardiello, MD, PhD, University of Campania,Axel Grothey, MD, West Cancer Center & Research Institute,Heinz-Josef Lenz, MD, FACP, USC Norris Comprehensive Cancer Center

June 29th 2020

Later Lines of Therapy for mCRC

ByFortunato Ciardiello, MD, PhD, University of Campania,Axel Grothey, MD, West Cancer Center & Research Institute,Heinz-Josef Lenz, MD, FACP, USC Norris Comprehensive Cancer Center

June 29th 2020

Second-Line Treatment for mCRC

ByFortunato Ciardiello, MD, PhD, University of Campania,Axel Grothey, MD, West Cancer Center & Research Institute,Heinz-Josef Lenz, MD, FACP, USC Norris Comprehensive Cancer Center

June 29th 2020

Initiating Therapy for mCRC

ByFortunato Ciardiello, MD, PhD, University of Campania,Axel Grothey, MD, West Cancer Center & Research Institute,Heinz-Josef Lenz, MD, FACP, USC Norris Comprehensive Cancer Center

June 29th 2020

Continuum of Care for Metastatic CRC

ByFortunato Ciardiello, MD, PhD, University of Campania,Axel Grothey, MD, West Cancer Center & Research Institute,Heinz-Josef Lenz, MD, FACP, USC Norris Comprehensive Cancer Center

June 29th 2020

Latest Updated Articles

Role of I/O Combination Therapies in mCRC
June 29th 2020
Later Lines of Therapy for mCRC
June 29th 2020
$Therapeutic Agents in Relapsed/Refractory mCRC$
Therapeutic Agents in Relapsed/Refractory mCRC
June 29th 2020
Using I/O in MSI-H Tumors in mCRC
June 29th 2020
Key Trials in mCRC: I/O Combination Therapies
June 29th 2020
Second-Line Treatment for mCRC
June 29th 2020

Trending on OncLive

FDA Approves Dostarlimab for dMMR/MSI-H Locally Advanced Rectal Cancer

FDA Clears TumorSight Risk, an MRI-Derived AI Recurrence Tool for HR+, HER2– Breast Cancer

Dr Cercek on the FDA Approval of Dostarlimab for dMMR/MSI-H Locally Advanced Rectal Cancer

Vilamakitug Meets OS Threshold in Phase 1/2 Refractory mCRC Trial

Weigh Benefit Against Burden: Defining Lurbinectedin’s Role in a Shifting Small Cell Lung Cancer Landscape